Skip to content
10-K

Annual Report

ARCUTIS BIOTHERAPEUTICS, INC. ARQT

0001787306-25-000029

← back to feed
Filed
Feb 25, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Feb 19, 2025 118.64M sh
Long Term Debt FY 2024 · Dec 31, 2023 $201.8M
Cash And Equivalents FY 2024 · Dec 31, 2023 $88.4M
Current Liabilities FY 2024 · Dec 31, 2023 $46.67M
Total Liabilities FY 2024 · Dec 31, 2023 $252.7M
Current Assets FY 2024 · Dec 31, 2023 $330.43M
Total Assets FY 2024 · Dec 31, 2023 $341.37M
Shares Diluted FY 2024 · Dec 31, 2022 55.03M sh
Capex FY 2024 · Dec 31, 2022 $333K
Operating Cash Flow FY 2024 · Dec 31, 2022 −$257.72M
Eps Diluted FY 2024 · Dec 31, 2022 −$5.66
Eps Basic FY 2024 · Dec 31, 2022 −$5.66
Sga Expense FY 2024 · Dec 31, 2022 $122.12M
Rd Expense FY 2024 · Dec 31, 2022 $182.44M
Net Income FY 2024 · Dec 31, 2022 −$311.46M
Operating Income FY 2024 · Dec 31, 2022 −$301.63M
Cost Of Revenue FY 2024 · Dec 31, 2022 $754K
Revenue FY 2024 · Dec 31, 2022 $3.69M
Stockholders Equity FY 2024 · Dec 31, 2021 $297.68M